At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26 enrolled
Drug / intervention
Ustekinumabdrug
Likely dose
Ustekinumab 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigator-Initiated, Open-label Study Evaluating the Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
In Brief
A clinical study evaluating Ustekinumab for Moderate to Severe Palmar Plantar Psoriasis. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCentocor, Inc.
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionFeb 2012
Study CompletionApr 2012
TodayJul 2026
First PostedMar 19, 2010
Enrollment StartFeb 1, 2010
Primary CompletionFeb 1, 2012
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.3 years ago
Interventions
Ustekinumabdrug
Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.